Home>Mutual Funds>Compare>Compare Nippon India Pharma Fund Direct Growth with SBI Healthcare Opportunities Fund Direct Plan Growth
shareSHARE
Compare Funds
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
cancel

Nippon India Pharma Fund Direct Growth

Equity
Sectoral/Thematic
5.0 star
INVEST NOW
cancel

SBI Healthcare Opportunities Fund Direct Plan Growth

Equity
Sectoral/Thematic
3.0 star
INVEST NOW
add_circle_outline

Add a fund

Nippon India Pharma Fund Direct Growth

(62.6%)

SBI Healthcare Opportunities Fund Direct Plan Growth

(63.0%)
1Y
3Y
5Y
Fund Details
keyboard_arrow_up
RiskHighHigh-
Min SIP Amount₹100₹500-
Expense Ratio1.05%1.13%-
NAV₹269.5 (21-Jan-2021)₹216.3 (21-Jan-2021)-
Fund Started01-Jan-201301-Jan-2013-
Fund Size₹4,383Cr₹1,575Cr-
Returns
keyboard_arrow_up
1Y
62.6%
63.0%
-
3Y
21.3%
15.8%
-
5Y
14.3%
9.3%
-
Pros & Cons
keyboard_arrow_up
Pros
1. 3Y Returns are higher than the category average returns
2. 5Y Returns are higher than the category average returns
Found nothing so far.
-
Cons
1. Risk-adjusted returns are lower compared to the category
2. 1Y Returns are lower than the category average returns
1. Risk-adjusted returns are lower compared to the category
2. 3Y Returns are lower than the category average returns
3. 5Y Returns are lower than the category average returns
-

Holding Analysis

keyboard_arrow_up
Top 5
-
-
-
Top 20
-
-
-
P/E
-
-
-
P/B
-
-
-
Turn Over
-
-
-
Equity
-
-
-
Cash
-
-
-

Top Holdings

keyboard_arrow_up
Top 10 Holdings
Name
Assets
Aurobindo Pharma Ltd.
10.5%
Sun Pharmaceutical Inds. Ltd.
9.9%
Divi's Laboratories Ltd.
9.6%
Cipla Ltd.
9.0%
Lupin Ltd.
8.6%
Dr. Reddy's Laboratories Ltd.
7.3%
Cadila Healthcare Ltd.
6.5%
Gland Pharma Ltd.
6.5%
Thyrocare Technologies Ltd.
5.6%
Fortis Healthcare (India) Ltd
5.2%
Name
Assets
Aurobindo Pharma Ltd.
9.7%
Dr. Reddy's Laboratories Ltd.
9.6%
Divi's Laboratories Ltd.
9.1%
Cipla Ltd.
8.9%
Lupin Ltd.
8.8%
Sun Pharmaceutical Inds. Ltd.
6.8%
Narayana Hrudayalaya Ltd.
4.1%
Strides Pharma Science Ltd.
4.0%
Alkem Laboratories Ltd.
3.4%
Gland Pharma Ltd.
3.2%
-
Fund Manager
keyboard_arrow_up
Name
Sailesh Raj Bhan
Tanmaya Desai
-
Education

Mr. Bhan is an MBA (Finance) and CFA.

Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).

-

Experience

Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.

Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.

-

About Fund
keyboard_arrow_up
Description

Reliance Mutual Fund started their mutual fund on 30/06/1995 and its managing total assets of ₹2,32,169 Cr. Its ranked at 3 as per total assets at end of 30th Sep 2017.

SBI Mutual Fund started their mutual fund on 29/06/1987 and its managing total assets of ₹1,88,455 Cr. Its ranked at 5 as per total assets at end of 30th Sep 2017.

-

Launch Date
30 Jun 1995
29 Jun 1987
-
Custodian
Deutsche Bank
SBI SG Global Securities Services Pvt.Ltd.
-
Registrar & Transfer Agent
KFin Tech
Cams
-

Popular Comparisons

Motilal Oswal Multicap 35 Fund - Direct - Growth
17.8%
3Y Returns
VS
SBI Magnum Multi Cap Fund - Direct - Growth
16.3%
3Y Returns
Axis Bluechip Fund - Direct - Growth
17.4%
3Y Returns
VS
SBI Bluechip Fund - Direct - Growth
13.6%
3Y Returns
HDFC Small Cap Fund - Direct - Growth
22.9%
3Y Returns
VS
L&T Emerging Businesses Fund - Direct - Growth
22.4%
3Y Returns